Bernardo Rapoport

22PUBLICATIONS
64CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsImplementation science and evaluationHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Feb 25, 2026
WBC Growth Factors: ASCO Guideline Update.

Bishal Gyawali, Kari Bohlke, Jana K Dickter

|Nov 12, 2024
Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study.

Graham Cohen, Bernardo Rapoport, Sze W Chan

|May 08, 2024
Strategies to optimize the promise of checkpoint-targeted anti-cancer therapy.

Bernardo L Rapoport, Ronald Anderson

|Feb 22, 2024
Patient-reported symptom monitoring: using (big) data to improve supportive care at the macro-, meso-, and micro-levels.

Yan Wang, Matthew J Allsop, Joel B Epstein

|Dec 19, 2023
2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.

Ian Olver, Rebecca Clark-Snow, Christina H Ruhlmann

|Dec 17, 2023
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.

Bernardo Leon Rapoport, Jørn Herrstedt, Rebecca Clark Snow

Pageof 4

Frequent Collaborators

5 joint publications

Ronald Anderson

4 joint publications

Teresa Smit

3 joint publications

Helen C Steel

2 joint publications

Annette J Theron